睿知中国疾病研究地图
候选清单0

温州温州医科大学

温州医科大学附属第一医院

First Affiliated Hospital of Wenzhou Medical University

在本站收录的 53 种疾病中,这家医院列在其中 23 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

温州医科大学附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma8 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma6 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma96 篇牵头论文牵头 2 项开放试验
  4. 胃癌Stomach cancer55 篇牵头论文牵头 3 项开放试验
  5. 骨肉瘤Osteosarcoma1 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour3 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma6 篇牵头论文
  9. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia2 篇牵头论文
  10. β 地中海贫血Beta thalassaemia2 篇牵头论文
  11. 血友病 AHaemophilia A0 篇牵头论文
  12. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder5 篇牵头论文
  13. 重症肌无力Myasthenia gravis4 篇牵头论文
  14. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
  15. 特发性肺纤维化Idiopathic pulmonary fibrosis5 篇牵头论文
  16. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis5 篇牵头论文
  17. 白塞病Behçet disease1 篇牵头论文
  18. IgA 肾病IgA nephropathy6 篇牵头论文
  19. 戈谢病Gaucher disease0 篇牵头论文
  20. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  21. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
  22. 先天性膈疝Congenital diaphragmatic hernia0 篇牵头论文
  23. Leber 遗传性视神经病变Leber hereditary optic neuropathy1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、尤文肉瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、尼曼-匹克病 C 型、成骨不全症、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 2220232024: 0020242025: 442025

温州有 1 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Immune Score Based Radiomics in Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2021-11
    登记号
    NCT05126160

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:浙江省肿瘤医院;另有 4 家列出的医院为研究中心宁波、杭州、武汉、温州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗技术影像与人工智能诱导/同步化疗
论文中的科室放疗科
牵头的论文8
  1. Optimal combination treatment for Locally Advanced Nasopharyngeal Carcinoma: A systematic review and Bayesian Network Meta-Analysis.2025American journal of otolaryngology
  2. The clinical value of FAPI PET/CT in delineating target volumes for nasopharyngeal carcinoma.2025European journal of nuclear medicine and molecular imaging免费全文
  3. Radiomics-guided generative adversarial network for automatic primary target volume segmentation for nasopharyngeal carcinoma using computed tomography images.2025Medical physics
  4. Deep learning dosiomics for the pretreatment prediction of radiation dermatitis in nasopharyngeal carcinoma patients treated with radiotherapy.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. Automatic detection and recognition of nasopharynx gross tumour volume (GTVnx) by deep learning for nasopharyngeal cancer radiotherapy through magnetic resonance imaging.2023Radiation oncology (London, England)免费全文
  6. A nomogram model based on pre-treatment and post-treatment MR imaging radiomics signatures: application to predict progression-free survival for nasopharyngeal carcinoma.2023Radiation oncology (London, England)免费全文
  7. Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma - An updated meta-analysis and systematic review.2021American journal of otolaryngology
  8. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Immune Score Based Radiomics in Nasopharyngeal Carcinoma正在招募NCT05126160研究中心2021-11 启动
PubMed 以外找到的论文(未计入)5
  1. 847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial2024Annals of Oncology论文
  2. Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.2024Journal of Clinical Oncology会议摘要
  3. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncology会议摘要
  4. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figshare数据集
  5. miRNAs Associated with Nasopharyngeal Carcinoma: New Prognostic Biomarkers and Therapeutic Targets2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025

温州有 3 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题影像与人工智能放疗分子标志物与基因
论文中的科室消化/肝病科放疗科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 96 篇,占 0.7%。

牵头论文
96
2021–2025 年
牵头试验
7
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 202020212022: 171720222023: 191920232024: 222220242025: 16162025

温州有 2 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
    分期
    II期
    开始
    2026-04
    登记号
    NCT07381634

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:温州医科大学附属第一医院温州

  2. 正在招募
    Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
    分期
    未注明
    开始
    2026-03
    登记号
    NCT07495735

    年龄 18 岁 至 未注明(登记的条件)

    牵头:温州医科大学附属第一医院温州

  3. 正在招募
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07170345

    年龄 18 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州

  4. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  5. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  6. 即将招募
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07100236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、合肥、广州、杭州、温州、福州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现乙肝与肝硬化
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文96
  1. Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis.2026European radiology
  2. Development of a new nomogram for predicting recurrence in HCC with MVI following curative hepatectomy.2026International journal of surgery (London, England)
  3. Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving lenvatinib: a retrospective, multicenter cohort study.2025BMC cancer免费全文
  4. Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics.2025BMC cancer免费全文
  5. Analysis of high-risk factors for hepatocellular carcinoma after sustained virological suppression of chronic hepatitis B.2025BMC cancer免费全文
  6. Explainable machine learning model for predicting the transarterial chemoembolization response and subtypes of hepatocellular carcinoma patients.2025BMC gastroenterology免费全文
  7. Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN.2025Cell death & disease免费全文
  8. METTL3 inhibition promotes radiosensitivity in hepatocellular carcinoma through regulation of SLC7A11 expression.2025Cell death & disease免费全文
  9. Disulfiram/Cu targeting FOXO6 modulates sensitivity of hepatocellular carcinoma to lenvatinib via disrupt choline metabolic.2025Cellular signalling
  10. Melatonin reverses lenvatinib resistance in HCC by regulating the ATF4-NRF1 pathway mediated by ceramide synthase 6.2025Cellular signalling
  11. Demethoxycurcumin induces metabolic crisis and ATF4/ATF3/CHOP-dependent cell death in hepatocellular carcinoma.2025Chemico-biological interactions
  12. Integrated GMPS and RAMP3 as a signature to predict prognosis and immune heterogeneity in hepatocellular carcinoma.2025Gene
  13. Role of alphaII-spectrin and XPF interaction in Hepatocellular carcinoma.2025Gene
  14. Microwave ablation versus radiofrequency ablation for hepatocellular carcinoma in patients with decompensated cirrhosis.2025HPB : the official journal of the International Hepato Pancreato Biliary Association
  15. Visualization of protrusion-localized STAT3 mRNA using a self-powered lipidic nanoflare for predicting hepatocellular carcinoma metastasis.2025Mikrochimica acta免费全文
  16. Formosanin C induces autophagy-mediated cell death in hepatocellular carcinoma through activating DUSP1/AMPK/ULK1/Beclin1 signaling pathway.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  17. Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma.2025Scientific reports免费全文
  18. Alisertib impairs the stemness of hepatocellular carcinoma by inhibiting purine synthesis.2025The Journal of biological chemistry免费全文
  19. Carfilzomib activates ER stress and JNK/p38 MAPK signaling to promote apoptosis in hepatocellular carcinoma cells.2024Acta biochimica et biophysica Sinica免费全文
  20. Does an Aspirin a Day Take the MASLD Away?2024Advances in therapy
  21. Knockdown of ribosome RNA processing protein 15 suppresses migration of hepatocellular carcinoma through inhibiting PATZ1-associated LAMC2/FAK pathway.2024BMC cancer免费全文
  22. Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score.2024BMC cancer免费全文
  23. A novel prognostic signature and therapy guidance for hepatocellular carcinoma based on STEAP family.2024BMC medical genomics免费全文
  24. High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.2024Biochemical and biophysical research communications
  25. Hepatocellular carcinoma biomarkers screening based on hydrogel photonic barcodes with tyramine deposition amplified ELISA.2024Biosensors & bioelectronics
  26. Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma.2024Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas免费全文
  27. The significance of lipid metabolism reprogramming of tumor-associated macrophages in hepatocellular carcinoma.2024Cancer immunology, immunotherapy : CII免费全文
  28. Gut Microbiota as Mediator and Moderator Between Hepatitis B Virus and Hepatocellular Carcinoma: A Prospective Study.2024Cancer medicine免费全文
  29. ZNF300 promotes proliferation and migration of hepatocellular carcinoma by upregulating c-MYC gene expression.2024Clinics and research in hepatology and gastroenterology
  30. Suppressing MTERF3 inhibits proliferation of human hepatocellular carcinoma via ROS-mediated p38 MAPK activation.2024Communications biology免费全文
  31. Application of artificial intelligence radiomics in the diagnosis, treatment, and prognosis of hepatocellular carcinoma.2024Computers in biology and medicine
  32. The involvement of ROS-regulated programmed cell death in hepatocellular carcinoma.2024Critical reviews in oncology/hematology
  33. Associations between cuprotosis-related genes and the spectrum of metabolic dysfunction-associated fatty liver disease: An exploratory study.2024Diabetes, obesity & metabolism
  34. Synergistic activity of Enterococcus Faecium-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib.2024Gut microbes免费全文
  35. Single-cell-based molecular classification in systematic treatment of hepatocellular carcinoma: From in silico to bedside.2024Hepatology (Baltimore, Md.)
  36. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.2024Journal of internal medicine免费全文
  37. In vitro vascularized liver tumor model based on a microfluidic inverse opal scaffold for immune cell recruitment investigation.2024Lab on a chip
  38. ATP citrate lyase promotes the progression of hepatocellular carcinoma by activating the REGγ-proteasome pathway.2024Molecular carcinogenesis
  39. Crosstalk between endothelial progenitor cells and HCC through periostin/CCL2/CD36 supports formation of the pro-metastatic microenvironment in HCC.2024Oncogene
  40. Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression.2024Technology in cancer research & treatment免费全文
  41. Exploration and validation of a novel signature of seven necroptosis-related genes to improve the clinical outcome of hepatocellular carcinoma.2023BMC cancer免费全文
  42. Machine learning integrations develop an antigen-presenting-cells and T-Cells-Infiltration derived LncRNA signature for improving clinical outcomes in hepatocellular carcinoma.2023BMC cancer免费全文
  43. A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma.2023BMC medical genomics免费全文
  44. Matrix metalloproteinase-21 promotes metastasis via increasing the recruitment and M2 polarization of macrophages in HCC.2023Cancer science免费全文
  45. Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma.2023Cancer science免费全文
  46. lncRNA SNHG9 enhances liver cancer stem cell self-renewal and tumorigenicity by negatively regulating PTEN expression via recruiting EZH2.2023Cell and tissue research
  47. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.2023Clinical and translational medicine免费全文
  48. Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study.2023Clinical cancer research : an official journal of the American Association for Cancer Research
  49. Prognostic value of combined pre- and postoperative albumin-to-alkaline phosphatase ratio for patients with hepatocellular carcinoma undergoing trans-catheter chemoembolisation.2023Clinical radiology
  50. Targeting Hepatic Stellate Cell Death to Reverse Hepatic Fibrosis.2023Current drug targets
  51. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.2023Free radical biology & medicine
  52. The enrichment of the gut microbiota Lachnoclostridium is associated with the presence of intratumoral tertiary lymphoid structures in hepatocellular carcinoma.2023Frontiers in immunology免费全文
  53. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.2023Gut microbes免费全文
  54. The utility of Vision Transformer in preoperatively predicting microvascular invasion status of hepatocellular carcinoma.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  55. Reflections on prediction of microvascular invasion in hepatocellular carcinoma by pathology images.2023Hepatology international
  56. Hypoxia-induced exosomes facilitate lung pre-metastatic niche formation in hepatocellular carcinoma through the miR-4508-RFX1-IL17A-p38 MAPK-NF-κB pathway.2023International journal of biological sciences免费全文
  57. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  58. Rational Design of Gd-DOTA-Type Contrast Agents for Hepatobiliary Magnetic Resonance Imaging.2023Journal of medicinal chemistry
  59. Characterization of neutrophil extracellular traps related gene pair for predicting prognosis in hepatocellular carcinoma.2023The journal of gene medicine
  60. Glycolysis-Related Gene Signature Can Predict Survival and Immune Status of Hepatocellular Carcinoma.2022Annals of surgical oncology
  61. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.2022BMC cancer免费全文
  62. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.2022BMC cancer免费全文
  63. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.2022Cardiovascular and interventional radiology
  64. Role of ferroptosis in gastrointestinal tumors: From mechanisms to therapies.2022Cell biology international
  65. LncRNA HEPFAL accelerates ferroptosis in hepatocellular carcinoma by regulating SLC7A11 ubiquitination.2022Cell death & disease免费全文
  66. The Expressions and Functions of lncRNA Related to m6A in Hepatocellular Carcinoma from a Bioinformatics Analysis.2022Computational and mathematical methods in medicine免费全文
  67. Identification and Validation of Hub Genes Predicting Prognosis of Hepatocellular Carcinoma.2022Digestive surgery
  68. Microwave ablation versus radiofrequency ablation for subcapsular hepatocellular carcinoma: a propensity score-matched study.2022European radiology
  69. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.2022Frontiers in immunology免费全文
  70. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.2022Hepatology international
  71. Impact of sarcopenia on outcomes of patients undergoing liver resection for hepatocellular carcinoma.2022Journal of cachexia, sarcopenia and muscle免费全文
  72. CAFs-derived SCUBE1 promotes malignancy and stemness through the Shh/Gli1 pathway in hepatocellular carcinoma.2022Journal of translational medicine免费全文
  73. miRNA-432 and SLC38A1 as Predictors of Hepatocellular Carcinoma Complicated with Alcoholic Steatohepatitis.2022Oxidative medicine and cellular longevity免费全文
  74. Signature Construction and Molecular Subtype Identification Based on Pyroptosis-Related Genes for Better Prediction of Prognosis in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  75. Construction of a Metabolism-Related Long Non-Coding RNAs-Based Risk Score Model of Hepatocellular Carcinoma for Prognosis and Personalized Treatment Prediction.2022Pathology oncology research : POR免费全文
  76. Development and validation of a nomogram for predicting the cancer-specific survival of fibrolamellar hepatocellular carcinoma patients.2022Updates in surgery
  77. Liposomes co-loaded with ursolic acid and ginsenoside Rg3 in the treatment of hepatocellular carcinoma.2021Acta biochimica Polonica
  78. A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma.2021Aging免费全文
  79. Identification and validation of a glycolysis-associated multiomics prognostic model for hepatocellular carcinoma.2021Aging免费全文
  80. Letter: Hepatitis B and MAFLD - a consilience of risk factors for hepatocellular carcinoma.2021Alimentary pharmacology & therapeutics
  81. LncRNA AIRN influences the proliferation and apoptosis of hepatocellular carcinoma cells by regulating STAT1 ubiquitination.2021Archives of pharmacal research
  82. Inflammatory indexes in preoperative blood routine to predict early recurrence of hepatocellular carcinoma after curative hepatectomy.2021BMC surgery免费全文
  83. Development and Evaluation of Nomograms to Predict the Cancer-Specific Mortality and Overall Mortality of Patients with Hepatocellular Carcinoma.2021BioMed research international免费全文
  84. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.2021Bioengineered免费全文
  85. A signature of 13 autophagy‑related gene pairs predicts prognosis in hepatocellular carcinoma.2021Bioengineered免费全文
  86. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.2021Bioscience reports免费全文
  87. The value of preoperative systemic immune-inflammation index in predicting vascular invasion of hepatocellular carcinoma: a meta-analysis.2021Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas免费全文
  88. FGF21 in obesity and cancer: New insights.2021Cancer letters免费全文
  89. BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism.2021Cell death & disease免费全文
  90. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.2021Chinese medical journal免费全文
  91. Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients.2021Frontiers in public health免费全文
  92. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma.2021Journal of cellular and molecular medicine免费全文
  93. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis.2021Journal of cellular and molecular medicine免费全文
  94. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.2021Journal of experimental & clinical cancer research : CRRCT免费全文
  95. Identification of Biomarkers Based on Bioinformatics Analysis: The Expression of Ubiquitin-Conjugating Enzyme E2T (UBE2T) in the Carcinogenesis and Progression of Hepatocellular Carcinoma.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  96. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.2021Molecular medicine (Cambridge, Mass.)免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma正在招募NCT07495735牵头方2026-03 启动
  2. The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities正在招募NCT07381634牵头方II期2026-04 启动
  3. Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies状态不明NCT05448222牵头方2022-07 启动
  4. Relationship Between Microbiota and Prognosis of Hepatocellular Carcinoma(HCC) After Systemic Treatments状态不明NCT05443217牵头方2022-06 启动
  5. Relationship Between Liver Cancer and Sarcopenia状态不明NCT05339919牵头方2020-05 启动
  6. Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)状态不明NCT05543304牵头方2018-12 启动
  7. Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors状态不明NCT03302403牵头方(推断)不分期2017-12 启动
  8. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion正在招募NCT07170345研究中心2025-09 启动
  9. 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness即将招募NCT07100236研究中心2025-08 启动
  10. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  11. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  12. Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma已完成NCT06310590研究中心I期2023-08 启动
  13. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  14. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  15. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor进行中,不再招募NCT04008797研究中心I/II期2019-07 启动
  16. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 55 篇,占 0.6%。

牵头论文
55
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 121220222023: 3320232024: 141420242025: 14142025

温州有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial
    分期
    不分期
    开始
    2025-11
    登记号
    NCT07586384

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:温州医科大学附属第一医院温州

  2. 即将招募
    Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
    分期
    早期I期
    开始
    2026-09
    登记号
    NCT07394205

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:温州医科大学附属第一医院温州

  3. 即将招募
    Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07828899

    年龄 18 岁 至 85 岁(登记的条件)

    牵头:温州医科大学附属第一医院;另有 2 家列出的医院为研究中心济南、温州、石家庄

  4. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  5. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术营养与康复影像与人工智能
论文中的科室消化/肝病科普外/肝胆胰外科影像/核医学科放疗科
牵头的论文55
  1. CT-based delta-radiomics nomogram to assess tumor regression grade in locally advanced gastric cancer patients following neoadjuvant chemotherapy.2026Abdominal radiology (New York)
  2. Research advancements and evaluation of multifactor-induced murine models for gastric cancer.2025Animal models and experimental medicine免费全文
  3. CD2AP shapes a stromal reduced tumor microenvironment and contributes to immunotherapy in gastric cancer.2025BMC cancer免费全文
  4. Sarcopenia defined by the global leadership initiative in sarcopenia (GLIS) consensus predicts adverse postoperative outcomes in patients undergoing radical gastrectomy for gastric cancer: analysis from a prospective cohort study.2025BMC cancer免费全文
  5. Heterogeneity of T cells regulates tumor immunity mediated by Helicobacter pylori infection in gastric cancer.2025BMC cancer免费全文
  6. Machine learning assisted radiomics in predicting postoperative occurrence of deep venous thrombosis in patients with gastric cancer.2025BMC cancer免费全文
  7. Multi-regional feature integration on enhanced CT for lymph node metastasis prediction in gastric cancer: a novel radiomics approach.2025BMC medical imaging免费全文
  8. SNRPB promotes gastric cancer progression by regulating aberrant splicing of PUF60.2025Cell death & disease免费全文
  9. Stair climbing outperforms gait speed in predicting postoperative outcomes in patients undergoing radical gastrectomy for gastric cancer: A prospective study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. Muscle-specific strength is an alternative to muscle mass and grip strength for predicting outcomes in patients with gastric cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. Perioperative body composition changes and their clinical implications in patients with gastric cancer undergoing radical gastric cancer surgery: a prospective cohort study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  12. Human cytomegalovirus tegument protein UL23 promotes gastric cancer immune evasion by facilitating PD-L1 transcription.2025Molecular medicine (Cambridge, Mass.)免费全文
  13. Risk factors and prognostic impact of low physical performance in elderly patients undergoing radical gastrectomy for gastric cancer.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  14. Body composition analysis using CT at three aspects of the lumbar third vertebra and its impact on the diagnosis of sarcopenia.2025World journal of surgical oncology免费全文
  15. NOLC1 suppresses immunochemotherapy by inhibiting p53-mediated ferroptosis in gastric cancer.2025eLife免费全文
  16. Effects of esketamine on postoperative fatigue syndrome in patients after laparoscopic resection of gastric carcinoma: a randomized controlled trial.2024BMC anesthesiologyRCT免费全文
  17. Prognostic value of GLIM-defined malnutrition in combination with hand-grip strength or gait speed for the prediction of postoperative outcomes in gastric cancer patients with cachexia.2024BMC cancer免费全文
  18. Development and validation of a machine learning-based 18F-fluorodeoxyglucose PET/CT radiomics signature for predicting gastric cancer survival.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  19. An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study.2024Cancer medicine免费全文
  20. Computed tomography-based radiomics nomogram for predicting therapeutic response to neoadjuvant chemotherapy in locally advanced gastric cancer : A scale for treatment predicting.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  21. Characteristics and prognostic impact of cancer cachexia defined by the Asian Working Group for Cachexia consensus in patients with curable gastric cancer.2024Clinical nutrition (Edinburgh, Scotland)
  22. Utilizing machine learning to integrate single-cell and bulk RNA sequencing data for constructing and validating a novel cell adhesion molecules related prognostic model in gastric cancer.2024Computers in biology and medicine
  23. Enhanced PSO feature selection with Runge-Kutta and Gaussian sampling for precise gastric cancer recurrence prediction.2024Computers in biology and medicine
  24. Comparison between AWGC-cachexia and GLIM-malnutrition in patients with gastric cancer.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  25. Prognostic value and association of the age-adjusted Charlson Comorbidity Index with sarcopenia within patients with gastric cancer after radical resection.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  26. Correlation Between Basal Metabolic Rate and Clinical Outcomes in Gastric Cancer Patients: A Retrospective Study.2024Journal of investigative surgery : the official journal of the Academy of Surgical Research
  27. Integrated multi-omics analysis and machine learning developed a prognostic model based on mitochondrial function in a large multicenter cohort for Gastric Cancer.2024Journal of translational medicine免费全文
  28. Muscle attenuation, not skeletal muscle index, is an independent prognostic factor for survival in gastric cancer patients with overweight and obesity.2024Nutrition (Burbank, Los Angeles County, Calif.)
  29. Predictive nomogram for lymph node metastasis and survival in gastric cancer using contrast-enhanced computed tomography-based radiomics: a retrospective study.2024PeerJ免费全文
  30. miR-325-3p Reduces Proliferation and Promotes Apoptosis of Gastric Cancer Cells by Inhibiting Human Antigen R.2023Canadian journal of gastroenterology & hepatology免费全文
  31. Lactate Dehydrogenase and Risk of Readmission with Gastric Cancer: A Propensity Score Matching Analysis.2023Journal of investigative surgery : the official journal of the Academy of Surgical Research
  32. Evaluation the benefits of additional radiotherapy for gastric cancer patients after D2 resection using CT based radiomics.2023La Radiologia medicaRCT
  33. Cachexia Versus Sarcopenia in Clinical Characteristics and Prognostic Value After Radical Gastrectomy for Gastric Cancer: A Large-Scale Prospective Study.2022Annals of surgical oncology
  34. ASO Author Reflections: Comparison of Sarcopenia and Cachexia for Their Prognostic Value in Gastric Cancer Patients at Different TNM Stages After Gastrectomy.2022Annals of surgical oncology
  35. Integration of clinical and transcriptomics reveals programming of the lipid metabolism in gastric cancer.2022BMC cancer免费全文
  36. NF-κB-Related Metabolic Gene Signature Predicts the Prognosis and Immunotherapy Response in Gastric Cancer.2022BioMed research international免费全文
  37. Low SP1 SUMOylation-dependent SNHG17 upregulation promotes drug resistance of gastric cancer through impairing hsa-miR-23b-3p-induced Notch2 inhibition.2022Cellular oncology (Dordrecht, Netherlands)免费全文
  38. Bioinformatics Analysis Revealing the Correlation between NF-κB Signaling Pathway and Immune Infiltration in Gastric Cancer.2022Computational and mathematical methods in medicine免费全文
  39. Global leadership initiative in malnutrition (GLIM) criteria using hand-grip strength adequately predicts postoperative complications and long-term survival in patients underwent radical gastrectomy for gastric cancer.2022European journal of clinical nutrition
  40. Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo.2022European journal of pharmacology
  41. Impact of malnutrition diagnosed using Global Leadership Initiative on Malnutrition criteria on clinical outcomes of patients with gastric cancer.2022JPEN. Journal of parenteral and enteral nutrition
  42. Effect of Short-Term Preoperative Parenteral Nutrition Support for Gastric Cancer Patients with Sarcopenia: a Propensity Score Matching Analysis.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  43. Association of Sarcopenia and Low Nutritional Status with Unplanned Hospital Readmission after Radical Gastrectomy in Patients with Gastric Cancer: A Case-Control Study.2022Journal of healthcare engineering免费全文
  44. Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis.2022Scientific reports免费全文
  45. Genotyping Helicobacter pylori antibiotic resistance and virulence-associated genes in patients with gastric cancer in Wenzhou, China.2021Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  46. Prognostic value of small mother against decapentaplegic expression in human gastric cancer.2021Bioengineered免费全文
  47. Value of muscle quality, strength and gait speed in supporting the predictive power of GLIM-defined malnutrition for postoperative outcomes in overweight patients with gastric cancer.2021Clinical nutrition (Edinburgh, Scotland)
  48. Influence of body composition, muscle strength, and physical performance on the postoperative complications and survival after radical gastrectomy for gastric cancer: A comprehensive analysis from a large-scale prospective study.2021Clinical nutrition (Edinburgh, Scotland)
  49. Sarcopenia is a predictive factor of poor quality of life and prognosis in patients after radical gastrectomy.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  50. The relationship between the GLIM-defined malnutrition, body composition and functional parameters, and clinical outcomes in elderly patients undergoing radical gastrectomy for gastric cancer.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  51. Patterns of immune infiltration in gastric cancer and their clinical significance.2021Japanese journal of clinical oncology
  52. Identification of lncRNA-associated competing endogenous RNA networks for occurrence and prognosis of gastric carcinoma.2021Journal of clinical laboratory analysis免费全文
  53. C-Myc-activated long non-coding RNA LINC01050 promotes gastric cancer growth and metastasis by sponging miR-7161-3p to regulate SPZ1 expression.2021Journal of experimental & clinical cancer research : CR免费全文
  54. Laparoscopic versus open resection for elderly patients with gastric cancer: a double-center study with propensity score matching method.2021Langenbeck's archives of surgery
  55. Measurement of muscle quantity/quality has additional predictive value for postoperative complications and long-term survival after gastrectomy for gastric cancer in patients with probable sarcopenia as defined by the new EWGSOP2 consensus:2021Nutrition (Burbank, Los Angeles County, Calif.)
中文论文(未计入)1
  1. [Application of right-opening single flap valvuloplasty based on tubular stomach in gastrointestinal reconstruction after laparoscopic proximal gastrectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer即将招募NCT07828899牵头方不分期2026-10 启动
  2. Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer即将招募NCT07394205牵头方早期I期2026-09 启动
  3. Single-port Versus Conventional Laparoscopic Surgery for Radical Proximal Gastric Cancer: A Randomized Controlled Trial正在招募NCT07586384牵头方不分期2025-11 启动
  4. Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma已完成NCT01711242牵头方(推断)II期2012-01 启动
  5. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  6. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  7. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  8. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  9. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  10. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer已终止NCT02867839研究中心III期2017-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.04%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

温州有 14 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

温州有 2 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室消化/肝病科肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

温州有 4 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经外科神经内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.4%。

牵头论文
6
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
10
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 442025

温州有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-02
    登记号
    NCT07258511

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安

  2. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  3. 正在招募
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07555938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、南京、天津、广州、昆明、杭州、武汉、济南、温州、苏州、青岛

  4. 正在招募
    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
    分期
    III期
    开始
    2024-08
    登记号
    NCT06520176

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:宁波大学医学院附属医院;另有 6 家列出的医院为研究中心台州、宁波、杭州、温州

  5. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛

  6. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  7. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  8. 正在招募
    Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
    分期
    II期
    开始
    2022-07
    登记号
    NCT05594797

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、温州

  9. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  10. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层CAR-T 与细胞治疗

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Comprehensive analysis of exosome-related gene signature in multiple myeloma prognosis and immune microenvironment evaluation.2025Cancer immunology, immunotherapy : CII免费全文
  2. Genetic association between coffee consumption and multiple myeloma mediated by plasma metabolites: a Mendelian randomization study.2025Food & function
  3. Leveraging a disulfidptosis-based signature to characterize heterogeneity and optimize treatment in multiple myeloma.2025Frontiers in immunology免费全文
  4. Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.2025Frontiers in public health免费全文
  5. Matrine induces autophagic cell death by triggering ROS/AMPK/mTOR axis and apoptosis in multiple myeloma.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. Significance of alkaline Phosphatase After Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma.2023Clinical lymphoma, myeloma & leukemia
中文论文(未计入)1
  1. [Toxicity Management and Efficacy Evaluation of BCMA-CART in the Treatment of Relapsed and Refractory Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)26
  1. Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors状态不明NCT03302403牵头方(推断)不分期2017-12 启动
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma正在招募NCT07555938研究中心III期2026-06 启动
  3. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07258511研究中心III期2026-02 启动
  5. Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients正在招募NCT06520176研究中心III期2024-08 启动
  6. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  7. Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM正在招募NCT05594797研究中心II期2022-07 启动
  8. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  9. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  10. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  11. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  12. A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06934044研究中心I期2025-05 启动
  13. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  14. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  15. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  16. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  17. A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China已完成NCT05896774研究中心I期2023-06 启动
  18. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects状态不明NCT05646758研究中心I期2023-03 启动
  19. BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma已完成NCT05376345研究中心I期2022-09 启动
  20. Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant进行中,不再招募NCT05317416研究中心III期2022-03 启动
  21. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  22. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  23. Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma状态不明NCT04003168研究中心I期2019-07 启动
  24. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  25. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  26. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。

牵头论文
2
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

温州有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录
研究主题费城染色体与遗传学

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

温州有 1 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

温州有 3 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
论文中的科室病理/检验科
中文论文(未计入)1
  1. [Analysis of genetic variant in a Chinese pedigree with hereditary factor VIII deficiency].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 2220242025: 112025

温州有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断预防复发急性发作治疗
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 332025

温州有 1 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题生物制剂与补体抑制剂抗体与诊断常规免疫治疗
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

温州有 2 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.5%。

牵头论文
5
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

温州有 5 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

这些论文过半是实验室或动物研究。

牵头的论文5
  1. Decoding tamoxifen on idiopathic pulmonary fibrosis: integrating network toxicology and multi-omics.2026International journal of surgery (London, England)
  2. Fibrotic extracellular matrix microenvironment induces alveolar type II epithelial cell senescence via integrin-β1/FAK/YAP signaling pathway.2025International immunopharmacology
  3. Demethyleneberberine ameliorates pulmonary fibrosis by inhibiting the NLRP3 inflammasome and the epithelial-mesenchymal transition.2025International immunopharmacology
  4. Exploring the causal effect between lipid-modifying drugs and idiopathic pulmonary fibrosis: a drug-target Mendelian randomization study.2024Lipids in health and disease
  5. WSB1, a Hypoxia-Inducible E3 Ligase, Promotes Myofibroblast Accumulation and Attenuates Alveolar Epithelial Regeneration in Mouse Lung Fibrosis.2024The American journal of pathology
早期论文(2016–2020 年)1
  1. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis.2019Nature communications
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Anlotinib Capsules in the Treatment for IPF/PF-ILDs进行中,不再招募NCT05828953牵头方II期2021-09 启动
  2. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.6%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

温州有 2 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

温州有 3 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Unveiling the Reason for Syncope Associated With Cardiac Nodules.2025Pacing and clinical electrophysiology : PACE
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease已终止NCT04609397研究中心II期2020-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 3320232024: 1120242025: 112025

温州有 7 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文6
  1. Impact of intrarenal arterial lesions on prognosis of IgA nephropathy: insights from a retrospective cohort study.2025Renal failure
  2. An enhanced machine learning approach for effective prediction of IgA nephropathy patients with severe proteinuria based on clinical data.2024Computers in biology and medicine
  3. Clinical Significance of Persistent Hematuria Degrees in Primary IgA Nephropathy: A Propensity Score-Matched Analysis of a 10-Year Follow-Up Cohort.2023American journal of nephrology
  4. Clinical significance of intrarenal vascular lesions in non-hypertensive patients with IgA nephropathy.2023Journal of nephrology
  5. Clinical significance of massive proteinuria in primary IgA nephropathy with and without nephrotic syndrome: a single center cohort study.2023Renal failure
  6. Clinicopathological and prognostic study of IgA-dominant postinfectious glomerulonephritis.2021BMC nephrology
中文论文(未计入)1
  1. [Progress in IgA-dominant infection-related glomerulonephritis].2023Zhonghua nei ke za zhi
早期论文(2016–2020 年)5
  1. Association between lifestyle, gender and risk for developing end-stage renal failure in IgA nephropathy: a case-control study within 10 years.2019Renal failure
  2. Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study.2018Human pathology
  3. Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.2018Immunologic research
  4. Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study.2017BMC nephrology
  5. Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy.2017Scientific reports
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年没有牵头戈谢病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

温州有 1 家医院列在戈谢病下全国有 41 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

温州有 4 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

温州有 1 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年没有牵头先天性膈疝的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

温州有 3 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. A neonate with dyspnoea.2016BMJ (Clinical research ed.)

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

温州有 2 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

温州医科大学附属第一医院

First Affiliated Hospital of Wenzhou Medical University

温州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
First Affiliated Hospital of Wenzhou Medical University Wenzhou; First affiliated hospital of Wenzhou medical University; First Affiliated Hospital of Wenzhou Medical College; First Affiliated Hospital of Wenzhou Medical Uinversity; First Provincial Wenzhou Hospital of Zhejiang

提出更正下载数据